Loading organizations...
SixPeaks Bio is focused on developing innovative treatments for cardiometabolic diseases, particularly obesity, by targeting muscle preservation and enhancing metabolic fitness.
SixPeaks Bio has raised $30.0M across 1 funding round.
SixPeaks Bio has raised $30.0M in total across 1 funding round.
SixPeaks Bio has raised $30.0M in total across 1 funding round.
SixPeaks Bio's investors include Aisling Capital, Hbm Partners, Ali Behbahani, Versant Ventures.
SixPeaks Bio has raised $30.0M across 1 funding round. Most recently, it raised $30.0M Series A in May 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 1, 2024 | $30M Series A | — | Aisling Capital, HBM Partners, ALI Behbahani, Versant Ventures | Announced |
SixPeaks Bio is a biotechnology company developing therapies for healthy weight loss, focusing on preserving skeletal muscle mass during treatment with GLP-1 receptor agonists (GLP1 RAs) to address obesity and cardiometabolic diseases.[1][2][3] Its lead program features a dual-specific antibody targeting activin type IIA and IIB receptors (ActR2A/B), with a pipeline of innovative mAb-peptide-based polyfunctional products serving the healthcare sector.[1][2][3] Founded in 2022 in Basel, Switzerland, the company raised $30M in Series A funding from Versant Ventures and AstraZeneca, and was acquired by AstraZeneca in October 2025 for an upfront $170M plus up to $130M in future payments, at a valuation of $200M-$300M.[1][5][6]
SixPeaks Bio emerged in 2022 from Versant Ventures' Ridgeline Discovery Engine in Basel Technology Park, Switzerland, with the goal of creating improved therapies for healthy weight loss.[1][4][5] Key leaders include CEO Philip Larsen, with experience in anti-obesity agents from Bayer; SVP Estelle leading nonclinical development, previously at 3T Biosciences, Roche, and Novartis; and board members like Katrin (PhD from Max Planck) and Ratan from AstraZeneca's BioPharmaceuticals.[2] The idea stemmed from recognizing muscle loss as a limitation of GLP1 RAs, driving early collaboration with AstraZeneca, which provided funding and an acquisition option from launch.[3][5]
SixPeaks rides the GLP1 RA wave—exemplified by Wegovy and Zepbound—tackling the epidemic affecting over 1 billion people with obesity comorbidities, where muscle loss undermines long-term health.[3][5] Timing aligns with Big Pharma's obesity push, as AstraZeneca acquires to bolster its pipeline amid peers' deals, though muscle-preserving agents face hurdles like Eli Lilly's trial halts and FDA demands for weight loss efficacy.[5] Market forces favor it: surging demand for "healthy" weight solutions and Basel's biotech hub status accelerate development.[1][4] Its acquisition influences the ecosystem by validating ActR2 approaches and integrating into AstraZeneca's cardiovascular/metabolism portfolio.[2][5][6]
Post-acquisition, SixPeaks' assets will advance under AstraZeneca's resources, likely accelerating clinical trials for its ActR2A/B program toward IND/CTA filings.[2][5][6] Trends like multi-mechanism obesity drugs and precision conjugates will shape progress, potentially setting standards for muscle-sparing therapies despite development risks.[3][5] Its influence may grow by enabling AstraZeneca to compete in the $100B+ obesity market, evolving from startup innovator to integrated pharma powerhouse—exemplifying how targeted biotech fills critical gaps in blockbuster therapies.[1][5]
